1 Predicting cognitive decline in Alzheimer’s disease using minimal clinical features: A machine learning approach with the NACC cohort 10.61882/jcc.6.2.7 1 Early identification of individuals at risk for Alzheimer’s disease–related cognitive decline is crucial for timely intervention and clinical trial enrollment. We developed a machine learning model using only five routinely collected clinical variables, age, sex, education, baseline Mini-Mental State Examination (MMSE), and Clinical Dementia Rating–Sum of Boxes (CDR-SB), to predict cognitive decline three years in advance. Using a sample of 2,000 participants from the National Alzheimer’s Coordinating Center (NACC) dataset, a Random Forest classifier achieved 94% accuracy and an AUC of 0.98 on an independent test set. Feature importance analysis confirmed that CDR-SB and MMSE were the strongest predictors, collectively accounting for 66% of model relevance. This approach offers a low-cost, scalable tool for risk stratification, particularly valuable in low-resource settings and primary care, where advanced diagnostics are unavailable. 1 7 Maryam Tarkesh Esfahani Department of Physics, Isfahan University of Technology Iran maryamtarkesh75@gmail.com Mini-Mental State Examination (MMSE) Clinical Dementia Rating (CDR) Random forest Minimal-data prediction Early detection Prognostic modeling [1] M.N. Rossor, N.C. Fox, C.J. Mummery, J.M. Schott, J.D. Warren, The diagnosis of young-onset dementia, The Lancet Neurology 9(8) (2010) 793–806.##[2] S. Hendriks, K. Peetoom, C. Bakker, R. Koopmans, W. van der Flier, J. Papma, F. Verhey, Y.O.D.E.S. Group, M. de Vugt, S. Köhler, Global incidence of young‐onset dementia: a systematic review and meta‐analysis, Alzheimer's and dementia 19(3) (2023) 831–843.##[3] S. Hendriks, K. Peetoom, C. Bakker, W.M. Van Der Flier, J.M. Papma, R. Koopmans, F.R. Verhey, M. De Vugt, S. Köhler, A. Withall, Global prevalence of young-onset dementia: a systematic review and meta-analysis, JAMA neurology 78(9) (2021) 1080–1090.##[4] S. Matsumoto, T. Hosoi, M. Yakabe, K. Fujimori, J. Tamaki, S. Nakatoh, S. Ishii, N. Okimoto, M. Akishita, M. Iki, Early‐onset dementia and risk of hip fracture and major osteoporotic fractures, Alzheimer's and Dementia 20(5) (2024) 3388–3396.##[5] N. Taveira, G.R.F. Collaborators, Global burden of 87 risk factors in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019, (2020).##[6] G.-R. Manuel, C. Manuel Moreno, S. Juan Manuel Górriz, M.-C. Adolfo, Diagnosis of Neurodegenerative Diseases: The Clinical Approach, Current Alzheimer Research 13(5) (2016) 469–474.##[7] C. Pedro, M. Marina, T. Adolfo, Blood-Based Biomarkers of Alzheimer´s Disease: Diagnostic Algorithms and New Technologies, Current Alzheimer Research 13(4) (2016) 450–464.##[8] A. Nandi, N. Counts, S. Chen, B. Seligman, D. Tortorice, D. Vigo, D.E. Bloom, Global and regional projections of the economic burden of Alzheimer's disease and related dementias from 2019 to 2050: A value of statistical life approach, eClinicalMedicine 51 (2022).##[9] P. Leber, Guidelines for the clinical evaluation of antidementia drugs, (1990).##[10] R.B. Mani, The evaluation of disease modifying therapies in Alzheimer's disease: a regulatory viewpoint, Statistics in medicine 23(2) (2004) 305–314.##[11] J.C. Morris, Clinical dementia rating: a reliable and valid diagnostic and staging measure for dementia of the Alzheimer type, International psychogeriatrics 9 (1997) 173–176.##[12] J.F. Quinn, R. Raman, R.G. Thomas, K. Yurko-Mauro, E.B. Nelson, C. Van Dyck, J.E. Galvin, J. Emond, C.R. Jack, M. Weiner, Docosahexaenoic acid supplementation and cognitive decline in Alzheimer disease: a randomized trial, Jama 304(17) (2010) 1903–1911.##[13] N. Coley, S. Andrieu, M. Jaros, M. Weiner, J. Cedarbaum, B. Vellas, Suitability of the Clinical Dementia Rating-Sum of Boxes as a single primary endpoint for Alzheimer’s disease trials, Alzheimer's and Dementia 7(6) (2011) 602–610. e2.##[14] L.S. Schneider, M. Sano, Current Alzheimer's disease clinical trials: methods and placebo outcomes, Alzheimer's and dementia 5(5) (2009) 388–397.##[15] W.J. Burke, J.P. Miller, E.H. Rubin, J.C. Morris, L.A. Coben, J. Duchek, I.G. Wittels, L. Berg, Reliability of the Washington University clinical dementia rating, Archives of neurology 45(1) (1988) 31–32.##[16] M. Storandt, E.A. Grant, J.P. Miller, J.C. Morris, Longitudinal course and neuropathologic outcomes in original vs revised MCI and in pre-MCI, Neurology 67(3) (2006) 467–473.##[17] B.J. Snider, A.M. Fagan, C. Roe, A.R. Shah, E.A. Grant, C. Xiong, J.C. Morris, D.M. Holtzman, Cerebrospinal fluid biomarkers and rate of cognitive decline in very mild dementia of the Alzheimer type, Archives of neurology 66(5) (2009) 638–645.##[18] S.E. O’Bryant, S.C. Waring, C.M. Cullum, J. Hall, L. Lacritz, P.J. Massman, P.J. Lupo, J.S. Reisch, R. Doody, T.A.s.R. Consortium, Staging dementia using Clinical Dementia Rating Scale Sum of Boxes scores: a Texas Alzheimer's research consortium study, Archives of neurology 65(8) (2008) 1091–1095.##[19] A. Anwar, Q. Kanwal, A. Sadiqa, T. Razaq, I.H. Khan, A. Javaid, S. Khan, E. Tag-Eldin, M. Ouladsmane, Synthesis and antimicrobial analysis of high surface area strontium-substituted calcium phosphate nanostructures for bone regeneration, International Journal of Molecular Sciences 24(19) (2023) 14527.